Also in this playlist...
This transcript is automatically generated
All right welcome back to -- take -- really existing guest and -- and technology out there that a lot of people talking.
In the medical community on Bennett -- talk a lot about medical technology in the last few weeks we've brought on a Frank Reynolds and the chairman and CEO Ed in -- therapeutics he joined this in New York frank thanks for joining us government.
You don't people who haven't seen this video almost -- when it is and you've you've been able to develop the ability to had announced on human trials.
Ought to -- allow monkey that's paralyzed to basically walk.
Huge huge when it comes down to of course the medical community for so many people out -- dealing with spinal injuries.
-- explain -- layman's terms how this works and what have been some of the highlights so far.
Yeah -- so -- gala people aren't aware but up to 90% of patients in arrive in the emergency room after a traumatic spinal cord injuries from a car accident or fall.
90% of them are gonna go to a bleeding and inflammation process over three weeks and puts them in a wheelchair for life.
So really when they arrived -- ruined they want they're not -- you know shouldn't be -- -- -- if we do have a chance intervene early.
And we've developed -- materials at Harvard and MIT.
About -- -- and MIT Bob is number one in the history of medical invention.
We develop these materials -- can be put into the nervous system they can be used alone to provide structural support to damaged tissue.
And what that -- tissue dies after knee injuries that clings onto the scaffold and provides structural support to it and then those cells survive and thrive.
They can also be used then and enhance them to include drugs -- -- And you know we -- human study coming up to you mentioned we -- the first accompanied every approved to start -- studying spinal cord injury using bomb materials.
And a lot of people in that are in wheelchairs or chronic injuries.
You know we'll say to me -- for the acute injury can help me but it's very important scaffold it's going to be a scaffold its leveraged to -- stem cells -- it.
When the patient's own cells or any other type -- -- -- development happened to treat a spot where injury.
And then the -- and support those cells and provide that that bridge you can say to a bridge to lesions.
The chronic scar that people who -- is currently -- So it's a very -- technology first we want to use it to prevent people from going -- wheelchairs to mitigate the bleeding and inflammation after injury.
And want to be in the first day or so after that injury.
And then of course we enhance it would cells in -- providing treatment for people are currently in wheelchairs.
You know when they're in wheelchairs have a scar that really needs to be removed and you know there's a lot of intervention is out there are trying to would have been working on it for a good 3040 years.
And you know what our intervention we do believe we can surgically removed the scar tissue and implement our scout for right away -- -- -- -- that structural support.
You don't end up with a significant scarring that normally comes with found removal of scar.
So the world and face which I don't know what to do -- -- on a corner we have a solution for.
Yeah Africa much questions for that first one is so.
-- -- It is severed penis still be applied -- he takes its most of those patients die unfortunately severing usually especially cervical injuries most of the severing -- -- up -- -- cervical area we -- and has a lot of movement and observing the court.
And of course they lose that can ability to breathe and a lot of them typically die.
So -- -- the first human the first technology is -- for contusion injuries it will before severed spinal cord you could say.
Although small servings may benefit from it down the road we'll have to see but right now the first technology -- for contusion injury -- injury like a car accident.
Right so our people home obviously aren't aren't medically trained so.
I didn't even realize that's a lot of people that are paralyzed in various ways depending on where they knew that realization begins its -- your -- scar tissue.
And and damage to the spinal -- not in -- of this.
This potentially could help heal that.
That's correct so again 90% of patients in Iran -- -- room are they gonna go through -- an inflammation over three weeks.
That results in the permanent scarring that prevents signaling from getting through the spinal cords to allow movement -- -- failing.
So will do is willing to be in the first couple days that -- and inflammation when that advances that would have.
And then -- reduce scarring you'll get functional recovery so patients who recover based on the level of initial injury that would recover certain -- -- functional recovery.
What about people that are.
As you -- -- had the issue -- maybe.
Three -- 4510 years ago.
-- their -- their violent issue to their to the spinal cord with scar tissue and such I mean is desist this possibly help for them as well as assist for new pace.
Yes absolutely and that that's us and our first studies for the acute population new patients.
But then we would leverage -- with the patient's own cells or other cells and other people are developing.
We would add them to ask apple and then we would surgically remove the scar tissue that's already in place because -- and we didn't intervene in the first few weeks and those patients.
So we would surgically remove that's partition to quickly plug in -- scaffold with cells.
And then bridge they basically healthy tissue healthy tissue removed that scar.
Now who's a plausible that -- mentioned you missed a couple different hospitals and locations -- You're seeking investors as a kind kind of give us a background of of the company and what's going on it and where this.
All taking place finish or somewhere publicly traded company were trading on the OTC right now we're in the process of up -- tied to New York Stock Exchange of the NASDAQ.
The stock is so up over -- 120% in the last year were up about or over a 120% they share.
Were up I think -- percent just this month it's actually very well of course people are aware that we're doing something that was haven't done before.
But more importantly we're gonna leverage it for other treatments in September will be -- to the FDA pain treatment for people are needed desks.
So there's four point two million people every quarter.
Getting -- four point two million shots supporters in the United States for people -- this and other pain problems awaiting a time released drug.
Pain relieving treatments into the spinal column.
Starting hopefully after September -- weeks and -- application to the FDA.
So again there's a lot of flexibility with the treatments.
You know we can use -- -- spinal -- we can use it for pain treatment.
And we believe that there will be future treatments for parkinson's Ellis Island so two very big breakthrough and have a material that doesn't cause any bleeding artery inflammation -- Having side affects -- consequences to it.
Frank to really two questions one Ella she's you mentioned possibly as well well LS of course is -- the mile and this nation of the right nervous system -- so I'm obviously.
You know take 2000 Andy -- scaffold is all about regeneration.
So that of course would re mile -- -- the court itself yes.
But it and a lot -- that we really quickly -- -- people find out more about -- humid September is an ideal date.
Maybe to get things rolling men but I mean people wanna find out more shows we're gonna go but it didn't it below therapeutics dot com is our website you can always email us at info and then -- therapeutics dot -- We have a website up and be about therapeutics that TV if people like to watch a series of the videos.
That is a lot of information website with its great web -- I think it could well rewarded -- -- -- emails can be sent to info -- therapeutics can't we get back very quickly.
All right Frank Reynolds joining us from New York he's the chairman and CEO chairman of the border sealed and -- therapeutics.
Talk about an amazing really amazing advancement and we we hope the human trials -- well for you guys will definitely check in with you.
If you want to find out more you go to -- website as he mentioned thanks again for joining us from new York and it was -- and about the advancement in medical technology yeah thank you very much from us.
All right fantastic stuff.
We're probably go to break now stay with us we come back we have more -- more gadgets of course you're watching tactic if you -- -- -- -- your policy on on Twitter at Adam Housley.
All right here of course on foxnews.com you can -- -- in there.
Also on FaceBook and even on Linkedin so feel free to chime in with anything you wanna talk about and he gets you -- -- see -- questions you have but if you would talk to so far.
Filter by section